NSCLC Coverage From Every Angle
Advertisement
Advertisement

Recent News

2019 Thoracic Cancers Symposium: Local Consolidative Therapy for Oligometastatic NSCLC
AACR 2019: Clinical Utility of Cell-Free DNA Liquid Biopsy in Metastatic Lung Cancer
2019 ASCO-SITC Symposium: Neoadjuvant Atezolizumab in NSCLC
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
2019 ASCO-SITC Symposium: Vaccine Plus Nivolumab in Lung Cancer
FDA Grants Priority Review for Entrectinib in ROS1-Positive NSCLC
Optimal Timing of Surgical Resection for NSCLC
2019 STS: Novel Predictive Tool for Prolonged Air Leak After Lung Cancer Surgery
2019 STS: Imaging Nanoagent for Sentinel Lymph Node Mapping in Lung Surgery
2019 STS: How Socioeconomic Status Impacts Outcomes in Non–Small Cell Lung Cancer
2019 STS: Impact of Regionalization of Lung Cancer Surgery on Outcomes
2019 STS: Stage Correlation, Guideline-Concordant Care, and Survival in NSCLC
FDA Accepts sBLA for Atezolizumab Plus Chemotherapy in First-Line Treatment of Metastatic NSCLC
2019 STS: Opioid Use Varies Among Elderly After Lung Resection
FDA Expands Pemetrexed Indication With Pembrolizumab and Chemotherapy in First-Line Treatment of NSCLC
2019 STS: Can Patients Over Age 90 Benefit From NSCLC Treatment?
Academic vs. Community-Based Centers: Survival Disparities Among Patients With NSCLC?
KEYNOTE-010 in Advanced NSCLC: Long-Term Survival Benefit With Pembrolizumab
How Accurate Are NCDB Comorbidity Assessments in Lung Cancer and Other Resected Tumors?
OAK Trial: Disease Progression With Atezolizumab vs Chemotherapy in NSCLC
First-Line Immunotherapy Combination in Lung Cancer
Early Research of Birabresib in Lung Cancer and Other Solid Tumors
Is More Frequent Surveillance Associated With Better Survival for Patients With NSCLC?
FDA Approves Atezolizumab Combination in First-Line Treatment of Metastatic Nonsqumous NSCLC
Radiation-Based Trimodality Therapy in Stage III NSCLC
Combined Immunotherapy Treatment Studied in Advanced Lung Cancer
Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors
FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion
Palliative and Supportive Care Symposium: Immunotherapy-Related Toxicities
ESMO 2018: Neoadjuvant Erlotinib in Stage IIIA-N2 Lung Cancer
ESMO 2018: Single-Agent Nazartinib in EGFR-Mutant Lung Cancer
ASTRO 2018: Nelfinavir in Stage III Locally Advanced Lung Cancer
ESMO 2018: Resistance Mechanisms in Patients Treated with Osimertinib for Lung Cancer
ESMO 2018: Uncommon EGFR Mutations in Lung Adenocarcinoma
FDA Approves Lorlatinib in ALK-Positive Metastatic NSCLC
FDA Approves Pembrolizumab With Chemotherapy as First-Line Treatment of Metastatic NSCLC
Are Immune-Related Adverse Events Similar in Men and Women?
ASTRO 2018: Survival Benefit Reported With Local Consolidative Therapy in Oligometastatic NSCLC
ESMO 2018: Early Results With Novel Monoclonal Antibody in Advanced Lung Cancer
ESMO 2018: Benefit From Exercise Reported in Advanced Lung Cancer
WCLC 2018: Poziotinib in NSCLC With Genetic Mutations
CHEST 2018: Update on Adherence to Lung Cancer Screening
WCLC 2018: Brigatinib Poised to Become New First-Line Treatment in ALK-Positive Lung Cancer
WCLC 2018: Smoking Cessation Services During Lung Cancer Screening
WCLC 2018: Lorlatinib Active in ROS1-Positive NSCLC
International Cancer Immunotherapy Conference: Early Study Results of Vaccine in HER2-Positive Cancers
WCLC 2018: Survival Benefit With Durvalumab After Chemoradiotherapy in Stage III NSCLC
WCLC 2018: Effect of Nivolumab on Intracerebral Response in NSCLC With Brain Metastases
WCLC 2018: Survival Benefit in Women Compared With Men
WCLC 2018: Immunotherapy for Lung Cancers With Oncogenic Driver Mutations
Dacomitinib Approved by the FDA for Metastatic NSCLC With Genetic Mutations
WCLC 2018: Entrectinib in ROS1-Positive NSCLC
WCLC 2018: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Early-Stage Disease
FDA Grants Priority Review to Pembrolizumab as First-Line Treatment in NSCLC Subset


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.